Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours

Trial Profile

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2019

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Advanced breast cancer; Prostate cancer; Skin cancer; Solid tumours
  • Focus Adverse reactions; Proof of concept
  • Sponsors LiPlasome Pharma; Oncology Venture
  • Most Recent Events

    • 24 Jun 2019 According to an Oncology Venture A/S media release, the company is using LiPlaCis DRP to track, match and treat patients with metastatic breast cancer.
    • 11 Mar 2019 According to an Oncology Venture A/S media release, First patient has been dosed in a phase II study.
    • 18 Dec 2018 Results form this trial in patients with metastatic breast cancer presented in an Oncology Venture A/S media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top